https://glpletter.com 2026-11-07T20:21:16.758Z daily 1 https://glpletter.com/sections/nanoparticle-and-peptide-therapeutics 2026-11-07T20:21:16.758Z weekly 0.5 https://glpletter.com/sections/drug-delivery-beyond-injections 2026-10-23T19:41:30.204Z weekly 0.5 https://glpletter.com/sections/emerging-glp-1-indications 2026-10-06T17:35:41.085Z weekly 0.5 https://glpletter.com/sections/glp-1-science-and-mechanisms 2026-10-09T18:45:31.984Z weekly 0.5 https://glpletter.com/sections/glp-1-side-effects-and-patient-experience 2026-10-27T18:02:55.460Z weekly 0.5 https://glpletter.com/sections/nose-to-brain-n2b-delivery 2026-09-26T05:50:23.013Z weekly 0.5 https://glpletter.com/sections/features 2026-10-20T19:41:50.371Z weekly 0.5 https://glpletter.com/authors/tobias-wrenfield 2026-11-07T20:21:16.758Z weekly 0.4 https://glpletter.com/authors/mei-lin-tso 2026-11-07T20:21:16.758Z weekly 0.4 https://glpletter.com/authors/amara-osei-bonsu 2026-11-07T20:21:16.758Z weekly 0.4 https://glpletter.com/authors/priya-subramaniam 2026-11-07T20:21:16.758Z weekly 0.4 https://glpletter.com/posts/university-foundational-ip-versus-late-stage-formulation-patents-as-the-real-moa https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/25e17580-dd73-4284-a11e-3c93954e2721.jpeg 2026-11-07T20:21:16.758Z monthly 0.7 https://glpletter.com/posts/dementia-and-addiction-biotechs-using-intranasal-nanoparticles-ranked-by-clinica https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/f6c2eb54-0fdd-46d8-bd1c-ef3a2ec7bc3b.jpeg 2026-11-06T19:06:28.028Z monthly 0.7 https://glpletter.com/posts/platform-company-versus-formulation-cro-in-peptide-delivery-and-why-the-business https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/49a0a910-61eb-4118-b6cd-5c170d0a64e2.jpeg 2026-11-05T20:46:30.842Z monthly 0.7 https://glpletter.com/posts/partnership-due-diligence-checklist-for-peptide-therapeutic-companies-with-two-o https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/537b5de6-50bf-4bcc-a66e-fa0c949de21c.jpeg 2026-11-04T19:21:51.751Z monthly 0.7 https://glpletter.com/posts/how-one-founding-ip-position-separates-the-most-credible-early-stage-intranasal https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/5fadbb77-344a-4898-bcc3-34fcb05343ac.jpeg 2026-11-03T20:41:28.640Z monthly 0.7 https://glpletter.com/posts/patent-vintage-and-claim-depth-decide-who-wins-the-nose-to-brain-nanoparticle-ip https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/8e54d808-d6b9-4cc0-9b4f-2a221686b371.jpeg 2026-11-02T19:16:45.885Z monthly 0.7 https://glpletter.com/posts/what-glp-letter-readers-should-ask-before-calling-a-peptide-delivery-company-a-p https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/e29ee9be-26e9-4f7b-8600-44ce1bd2cd82.jpeg 2026-11-01T18:41:16.692Z monthly 0.7 https://glpletter.com/posts/why-intranasal-nanoparticle-platforms-are-outpacing-injectable-bbb-bypass-strate https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/8e67edd8-d20b-4642-bd89-7e0620ab13af.jpeg 2026-10-31T18:46:31.803Z monthly 0.7 https://glpletter.com/posts/ranking-nose-to-brain-drug-delivery-platforms-by-bbb-bypass-efficiency-and-cns-i https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/afff2713-72bd-4167-84d5-9ab9915283b7.jpeg 2026-10-28T19:36:07.475Z monthly 0.7 https://glpletter.com/posts/the-behavioral-and-psychological-spiral-that-turns-glp-1-nausea-into-permanent-d https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/f85d7238-df5a-48d4-a979-3583bdfe1269.jpeg 2026-10-27T18:02:55.460Z monthly 0.7 https://glpletter.com/posts/practical-retention-protocols-clinicians-are-using-to-keep-nausea-affected-glp-1 https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/6d1d0078-110c-4b11-bb21-bb721ef61945.jpeg 2026-10-26T18:21:25.725Z monthly 0.7 https://glpletter.com/posts/olfactory-and-trigeminal-pathways-as-the-pharmacokinetic-bypass-for-bbb-excluded https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/72508331-e656-42ab-9824-3c22ffe110bf.jpeg 2026-10-25T17:25:57.275Z monthly 0.7 https://glpletter.com/posts/which-universities-hold-the-deepest-peptide-nanoparticle-patent-portfolios-and-w https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/50dd6bf3-4471-4274-8ee9-bf5e48c6433c.jpeg 2026-10-24T18:10:42.641Z monthly 0.7 https://glpletter.com/posts/needle-free-glp-1-delivery-routes-ranked-by-clinical-readiness https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/803e7488-8394-4a6f-8a87-5c5a736eb165.jpeg 2026-10-23T19:41:30.204Z monthly 0.7 https://glpletter.com/posts/early-stage-biotechs-betting-patented-nanoparticle-platforms-on-cns-peptide-indi https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/87dd8b04-6587-428e-bba2-8a18cd55073e.jpeg 2026-10-22T19:06:46.326Z monthly 0.7 https://glpletter.com/posts/licensing-the-core-polymer-nanoparticle-peptide-delivery-ip-means-tracing-it-bac https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/665b9cf5-d74f-4feb-a565-0337afb2ee02.jpeg 2026-10-21T18:02:31.261Z monthly 0.7 https://glpletter.com/posts/glp-1-patches-don-t-exist-yet-here-s-what-the-side-effect-data-would-look-like https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/e227f041-2b40-44eb-972b-1faeea25c354.jpeg 2026-10-20T19:41:50.371Z monthly 0.7 https://glpletter.com/posts/how-the-lungs-absorb-peptides-and-where-that-breaks-down-for-glp-1s https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/df992ba5-5c19-4a93-9f40-3f526938ef13.jpeg 2026-10-19T19:21:30.114Z monthly 0.7 https://glpletter.com/posts/columbia-university-nanoparticle-spinout-ip-versus-big-pharma-formulation-patent https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/dd67be10-984a-4161-91c6-43495d1471a3.jpeg 2026-10-18T19:36:02.316Z monthly 0.7 https://glpletter.com/posts/scoring-the-nose-to-brain-peptide-field-by-platform-depth-ip-age-and-cns-indicat https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/82bbd067-175b-44ad-95d1-58e7c0632127.jpeg 2026-10-16T17:56:43.855Z monthly 0.7 https://glpletter.com/posts/glp-1-receptor-agonists-as-neurological-pipeline-candidates-enabled-by-nose-to-b https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/0a5dfba8-c33f-4073-a8c0-f6a92dc805e9.jpeg 2026-10-15T17:56:38.811Z monthly 0.7 https://glpletter.com/posts/intranasal-glp-1-delivery-as-the-clinical-bridge-for-needle-averse-patients-who https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/2edbb6d9-6a5e-49b0-a9a1-2b2766944d1c.jpeg 2026-10-14T17:41:53.387Z monthly 0.7 https://glpletter.com/posts/why-glp-1-patches-have-not-made-it-to-market https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/30081909-41e2-4deb-bdf8-8bf05389b068.jpeg 2026-10-13T19:11:43.457Z monthly 0.7 https://glpletter.com/posts/what-inhaled-insulin-taught-us-about-delivering-peptides-through-the-lung https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/795b4024-9124-4713-80a6-b47eabdef390.jpeg 2026-10-12T19:26:17.887Z monthly 0.7 https://glpletter.com/posts/intellectual-property-strategy-for-nanoparticle-drug-delivery-platforms https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/db9d7e99-ee2a-410a-8a54-41208b75fa84.jpeg 2026-10-11T18:26:15.834Z monthly 0.7 https://glpletter.com/posts/does-tirzepatide-suppress-appetite-or-burn-fat-directly https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/c6713b2d-1ebe-448d-8426-acc41dbf7a2c.jpeg 2026-10-09T18:45:31.984Z monthly 0.7 https://glpletter.com/posts/glp-1-receptor-agonist-drug-class-overview https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/990bca25-1bd0-4cf8-8dd7-88638e803316.jpeg 2026-10-08T19:35:36.431Z monthly 0.7 https://glpletter.com/posts/muscle-and-lean-mass-loss-during-glp-1-therapy https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/9388f867-f262-4d2a-8507-c56095ae45f9.jpeg 2026-10-07T19:10:46.199Z monthly 0.7 https://glpletter.com/posts/glp-1-receptor-agonists-and-dementia-risk-reduction-research https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/9f40be63-1ad4-4ff3-ac47-22b6f1ae12ee.png 2026-10-06T17:35:41.085Z monthly 0.7 https://glpletter.com/posts/liraglutide-vs-semaglutide-structural-and-pharmacological-differences https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/59c44e19-ed2f-44f2-8d93-72da9240bbff.jpeg 2026-10-04T18:55:16.503Z monthly 0.7 https://glpletter.com/posts/mucosal-absorption-barriers-for-peptide-biologics https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/33105b15-f1cc-42e9-adf0-a22c612dfb42.jpeg 2026-10-03T19:44:46.094Z monthly 0.7 https://glpletter.com/posts/peptide-stability-engineering-for-non-injectable-formulations https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/5fd695d8-de8f-4a8d-acf4-710ef248054b.jpeg 2026-10-02T19:40:55.508Z monthly 0.7 https://glpletter.com/posts/companies-developing-intranasal-routes-for-glp-1-and-metabolic-peptide-delivery https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/2a0ddd7d-0743-49b1-97d7-ef9c2eacd1f9.jpeg 2026-10-01T18:36:38.238Z monthly 0.7 https://glpletter.com/posts/nanoparticle-platforms-engineered-for-direct-nose-to-brain-peptide-transport https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/b61756d1-0230-404c-a41f-78fdce9974f7.jpeg 2026-09-30T19:20:56.945Z monthly 0.7 https://glpletter.com/posts/nanoparticle-drug-delivery-systems-in-approved-therapies https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/43410980-aa9b-45e8-9289-264eedf539f0.jpeg 2026-09-30T17:16:53.632Z monthly 0.7 https://glpletter.com/posts/drugs-that-can-cross-the-blood-brain-barrier https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/cfe4eac2-ab4a-449d-8ae2-d77304142fef.jpeg 2026-09-30T16:21:37.454Z monthly 0.7 https://glpletter.com/posts/drug-delivery-nanoparticle-platform-types-compared https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/96711de0-c7f1-4985-a83c-8fabc9baa2bd.jpeg 2026-09-29T06:50:22.936Z monthly 0.7 https://glpletter.com/posts/approved-intranasal-cns-drugs-and-their-delivery-mechanisms https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/0e13392a-0f09-4a8f-8e48-42d184a196f9.jpeg 2026-09-26T05:50:23.013Z monthly 0.7 https://glpletter.com/posts/nasal-epithelium-barriers-to-cns-drug-delivery https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/70f7f0d9-7f47-4719-a142-8142caf31084.jpeg 2026-09-25T00:39:22.694Z monthly 0.7 https://glpletter.com/posts/nose-to-brain-delivery-in-neurodegenerative-disease-research https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/ef1640ce-3d07-45ad-a5c9-403722477fa2.jpeg 2026-09-22T18:30:14.012Z monthly 0.7 https://glpletter.com/posts/nose-to-brain-delivery-for-large-molecule-biologics https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/8d26b583-3576-400b-a859-89423902f4c2.jpeg 2026-09-20T18:49:21.936Z monthly 0.7 https://glpletter.com/posts/glp-1-side-effect-profile-and-treatment-discontinuation-rates https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/d11f6113-a0de-4cca-9cdf-400e52207ab1.jpeg 2026-09-19T19:19:15.959Z monthly 0.7 https://glpletter.com/posts/gastroparesis-risk-with-glp-1-agonist-use https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/f69fa05d-8a3a-4e8b-877b-cc0b1a3ebb1a.jpeg 2026-09-18T19:50:22.786Z monthly 0.7 https://glpletter.com/posts/glp-1-skin-and-hypersensitivity-reactions https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/21aefb6b-e168-42c8-a1a9-926876c05a0c.jpeg 2026-09-16T18:45:41.485Z monthly 0.7 https://glpletter.com/posts/glp-1-side-effects-after-stopping-treatment https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/cfec1511-68a9-43fe-8298-fa92f368591b.png 2026-09-15T23:33:53.970Z monthly 0.7 https://glpletter.com/posts/glp-1-gastrointestinal-mechanisms-behind-nausea-and-diarrhea https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/3bdc891d-b739-4f5e-949f-df82768ce51d.jpeg 2026-09-15T22:29:07.383Z monthly 0.7 https://glpletter.com/posts/glp-1-injection-site-reactions-and-subcutaneous-tissue-effects https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/a8ff8f11-65dc-4606-8a60-0f83f6f40e96.jpeg 2026-09-13T03:36:24.482Z monthly 0.7 https://glpletter.com/posts/duration-and-resolution-of-glp-1-nausea-and-vomiting https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/12ffa5f2-b1ed-4291-bec5-2e29f6952785.jpeg 2026-09-12T03:42:26.433Z monthly 0.7 https://glpletter.com/posts/glp-1-long-term-side-effects-in-chronic-users https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/7bd62b3f-9cb4-488f-8d8e-90552e674a95.jpeg 2026-09-11T03:27:48.434Z monthly 0.7 https://glpletter.com/posts/patient-adherence-measurement-methods-in-chronic-peptide-therapy https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/d9390c51-ab58-45d7-a907-133b657504ca.jpeg 2026-09-10T01:07:47.897Z monthly 0.7 https://glpletter.com/posts/sublingual-and-buccal-peptide-delivery-feasibility https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/897181b8-e4ee-46a9-952d-fabf55e0ec34.jpeg 2026-09-08T22:29:03.073Z monthly 0.7 https://glpletter.com/posts/long-acting-injectable-formulations-and-implantable-depots https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/da440118-85d0-4e36-b629-b643673bcf29.jpeg 2026-09-08T05:25:23.982Z monthly 0.7 https://glpletter.com/posts/transdermal-peptide-delivery-research-and-current-limits https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/3b6157f5-29cc-46fb-8019-ae40fd0a007b.jpeg 2026-09-05T21:48:15.886Z monthly 0.7 https://glpletter.com/posts/transdermal-peptide-delivery-technologies-in-development https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/6c5bc15f-c697-44f0-bbcd-df4075f7be05.jpeg 2026-09-04T18:45:15.569Z monthly 0.7 https://glpletter.com/posts/needle-aversion-and-injection-anxiety-in-chronic-disease-management https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/834b3ecf-33fe-4392-b5a1-7ddb84f4255a.jpeg 2026-09-03T18:44:42.887Z monthly 0.7 https://glpletter.com/posts/peptide-bioavailability-benchmarks-across-delivery-routes https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/996ab5d3-9bcf-43a0-8907-c10d222cf2ac.jpeg 2026-09-01T21:14:05.306Z monthly 0.7 https://glpletter.com/posts/injection-fatigue-and-device-innovation-in-biologic-delivery https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/72ccf6d4-915e-44c1-ac93-3e57fd05d54c.jpeg 2026-08-30T17:47:10.568Z monthly 0.7 https://glpletter.com/posts/subcutaneous-vs-alternative-delivery-routes-for-glp-1-therapeutics https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/949dd588-b520-433a-af43-fb846989eeca.jpeg 2026-08-29T18:27:13.499Z monthly 0.7 https://glpletter.com/posts/oral-semaglutide-bioavailability-and-absorption-limitations https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/341f0100-ff63-4f6f-a604-ff14c35d6793.png 2026-08-28T19:31:21.893Z monthly 0.7 https://glpletter.com/posts/glp-1-and-cardiovascular-risk-reduction-mechanisms https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/27fce4c4-3c16-4196-aa5c-db7248a74134.png 2026-08-27T17:36:39.147Z monthly 0.7 https://glpletter.com/posts/glp-1-agonists-in-non-alcoholic-fatty-liver-disease https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/9a832be3-b049-4489-ba2f-ee8b1dd98814.png 2026-08-26T21:52:26.944Z monthly 0.7 https://glpletter.com/posts/glp-1-effects-on-sleep-architecture-and-metabolic-recovery https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/8877f478-6f6a-4f23-971e-d25bd3400996.png 2026-08-25T19:32:45.448Z monthly 0.7 https://glpletter.com/posts/glp-1-receptors-in-nicotine-and-opioid-craving-reduction https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/19ed20ea-3dab-451d-be97-4903e61522a8.png 2026-08-25T17:18:39.162Z monthly 0.7 https://glpletter.com/posts/glp-1-agonists-and-parkinson-s-disease-neuroprotection https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/35167b36-0b1a-429f-b1cd-5a6e503b8687.png 2026-08-24T05:16:44.607Z monthly 0.7 https://glpletter.com/posts/glp-1-receptor-activation-and-opioid-craving-reduction https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/a6dc339d-8224-4986-9881-8463ebce9a12.png 2026-08-22T18:43:38.858Z monthly 0.7 https://glpletter.com/posts/obesity-brain-axis-and-hypothalamic-inflammation https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/4faff090-54b1-4796-a49b-8f0e7d965881.png 2026-08-21T17:48:44.693Z monthly 0.7 https://glpletter.com/posts/glp-1-drugs-and-parkinson-s-disease-neuroprotection https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/ababea63-bdf9-4588-8d83-3795ff13e6ea.png 2026-08-20T18:04:29.034Z monthly 0.7 https://glpletter.com/posts/glp-1-signaling-in-alzheimer-s-disease-models https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/a5274d45-4a21-40a9-81c7-e826d634b213.png 2026-08-19T17:28:29.578Z monthly 0.7 https://glpletter.com/posts/glp-1-signaling-in-alzheimer-s-disease-research https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/0a30bc06-90cb-4411-923f-274c63677e7b.png 2026-08-17T17:58:45.440Z monthly 0.7 https://glpletter.com/posts/glp-1-receptor-agonists-in-alcohol-use-disorder https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/c50d21ed-1dac-4039-b577-ab3ae5196b69.png 2026-08-16T17:28:28.702Z monthly 0.7 https://glpletter.com/posts/glp-1-receptors-and-dopamine-pathways-in-addiction https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/f07dd944-ebe2-49f2-8035-ad37cb00639a.png 2026-08-15T19:18:40.839Z monthly 0.7 https://glpletter.com/posts/glp-1-agonists-in-alcohol-use-disorder-research https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/b367f4d4-bba0-4686-b94c-bfc58fc5d911.jpeg 2026-08-14T18:53:39.568Z monthly 0.7 https://glpletter.com/posts/dual-glp-1-gip-receptor-agonists-compared https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/0784673e-8966-455b-8b82-7dbb51dac01e.jpeg 2026-08-13T19:23:42.899Z monthly 0.7 https://glpletter.com/posts/gip-mechanism-of-action-in-weight-loss https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/719a2865-f410-4f18-b955-81fc3288300a.png 2026-08-12T18:18:35.486Z monthly 0.7 https://glpletter.com/posts/dpp-4-degradation-of-glp-1-and-half-life-engineering https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/3deeee0e-2d18-4656-9d63-7804fb44c7b3.png 2026-08-12T13:23:08.950Z monthly 0.7 https://glpletter.com/posts/glp-1-physiology-beyond-the-pancreas https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/2b8d80c9-c9bc-414b-906d-2315caa3a5e3.jpeg 2026-08-11T13:38:44.184Z monthly 0.7 https://glpletter.com/posts/glp-1-and-gip-combined-mechanism-of-action https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/951ed4f4-5c85-404a-ba85-014c2d06a8f8.jpeg 2026-08-10T13:38:41.323Z monthly 0.7 https://glpletter.com/posts/molecular-structure-of-glp-1-receptor-agonists https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/10dfa40d-b70d-47db-9e91-aeec9af27d9d.jpeg 2026-08-09T13:28:43.397Z monthly 0.7 https://glpletter.com/posts/glp-1-signaling-pathway-in-metabolic-regulation https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/e0a6fc3a-b0ba-4182-97bf-7989568e4f17.jpeg 2026-08-08T13:28:37.144Z monthly 0.7 https://glpletter.com/posts/engineering-precision-nanoparticles-for-peptide-payloads https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/976addf2-1b54-4f20-8a53-49d3bd1bdbb8.png 2026-08-06T22:07:53.755Z monthly 0.7 https://glpletter.com/posts/nose-to-brain-drug-delivery-pathway-explained https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/61c4beb4-3d2d-4d98-8c95-617dc4dec26b.jpeg 2026-08-06T21:18:44.484Z monthly 0.7 https://glpletter.com/posts/oral-peptide-delivery-and-the-intestinal-barrier-problem https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/6cd505b8-15bf-453c-839a-74dfc90c5622.jpeg 2026-08-06T21:18:41.658Z monthly 0.7 https://glpletter.com/posts/nausea-mechanisms-in-injectable-glp-1-therapy https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/73b7647f-8922-4c87-b61a-881443b9a860.jpeg 2026-08-06T21:18:41.169Z monthly 0.7 https://glpletter.com/posts/glp-1-receptors-in-the-brain https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/836acba8-dbd0-458c-8c50-716f2ffe20aa.jpeg 2026-08-06T21:13:38.798Z monthly 0.7 https://glpletter.com/posts/glp-1-injection-discontinuation-rates-and-their-causes https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/745781ca-e382-4232-aeea-cd3ac94c9462.jpeg 2026-08-06T20:53:44.856Z monthly 0.7 https://glpletter.com/posts/olfactory-pathway-anatomy-and-drug-transport-mechanisms https://mcxtywzsmeezbwapdahq.supabase.co/storage/v1/object/public/canvas-images/5f272d29-583f-45c8-b4b7-3112e4c46010/canvas/3eaf0fce-0722-45f9-a146-a0ed8b9027da/generated/b127dc5c-fb1f-4c02-9788-45adf70be8b0.jpeg 2026-08-06T20:53:44.119Z monthly 0.7